ONC - BeOne Medicines AG News

Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms

https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-wi

BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For A

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today anno

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Ca

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160

BeOne Medicines' Topline Data From Second Interim Analysis of Phase 3 HERIZON-GEA-01 Trial of ZIIHER

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemother

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regime

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for moment

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unr

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

BeOne Medicines And Max Foundation Renew Partnership To Expand Access To BRUKINSA For The Treatment

Partnership serves low- and middle-income countries, with the program projected to support approxima

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasda

BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations U

Companies also enter a separate regional rights agreement granting BeOne exclusive development and c

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercializatio

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Na

defenseworld.net

Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd. – Sponsored ADR $ONC

Dimensional Fund Advisors LP increased its stake in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ: ON

TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the pr

RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai

Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises t

Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform

marketbeat.com

BeOne Medicines Q2 Earnings Call Highlights

BeOne Medicines NASDAQ: ONC reported second-quarter revenue of $1.7 billion, up 30% from a year earl

seekingalpha.com

BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript

BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estim

While the top- and bottom-line numbers for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense o

BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est

BeOne Medicines (NASDAQ:ONC) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.60

BeiGene Q2 Adj. EPS $3.84 Beats $1.44 Estimate, Sales $1.705B Beat $1.591B Estimate

BeiGene (NASDAQ:ONC) reported quarterly earnings of $3.84 per share which beat the analyst consensus

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. announced financial result

Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Reve

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Spons

defenseworld.net

BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its stake in BeOne Medicines Ltd. - Sponsored ADR (NASD

JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises

fool.com

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification a

BeOne Medicines Announces $300M Expansion Of Its Manufacturing And R&D Center In New Jersey; Total U

The expansion will increase BeOne's production capacity to manufacture its medicines and is expe

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. announced a $300 million

fool.com

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position

Executed under pre-established trading plan, this sale reduces the chief executive's direct holdings

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160;

Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403

Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and lowers

Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380

Jefferies analyst Faisal Khurshid upgrades BeOne Medicines (NASDAQ:ONC) from Hold to Buy and rais

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $451

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $416

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and rai

Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price Target

Citizens analyst Reni J. Benjamin reiterates BeOne Medicines (NASDAQ:ONC) with a Market Outperfor

BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy

BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progressio

BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibi

BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

BeOne Medicines Discloses Chinese Tax Settlement Of CNY446M; To Be Noted In Q2 GAAP Financial Result

As previously disclosed in the Quarterly Report on Form 10-Q filed by BeOne Medicines Ltd. (the &#34

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

Here's How Much You Would Have Made Owning BeOne Medicines Stock In The Last 10 Years

BeOne Medicines To Present Large Phase 3 Dataset Showing Sustained Benefit With BRUKINSA After Nearl

BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today anno

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Ben

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160;

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $436

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and